Future cardiology最新文献

A plain language summary of the SEQUOIA-HCM study: aficamten for symptomatic obstructive hypertrophic cardiomyopathy. SEQUOIA-HCM研究的简单语言总结：aficamten用于症状性阻塞性肥厚性心肌病。

IF 1.6

Future cardiology Pub Date : 2025-05-26 DOI: 10.1080/14796678.2025.2490362

Martin S Maron, Iacopo Olivotto, Marion van Sinttruije

引用次数: 0

An evaluation of the SavvyWire as a support wire for TAVR procedures. 对SavvyWire作为TAVR程序的支持线的评估。

IF 1.6

Future cardiology Pub Date : 2025-05-26 DOI: 10.1080/14796678.2025.2509458

Julio I Farjat-Pasos, Marisa Avvedimento, Josep Rodes-Cabau

引用次数: 0

Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis. 血管紧张素受体奈普利素抑制剂对STEMI患者的影响：系统回顾和荟萃分析。

IF 1.6

Future cardiology Pub Date : 2025-05-26 DOI: 10.1080/14796678.2025.2506350

Aymen Ahmed, Muhammad Umer Sohail, Muhammad Saad, Zara Naveed, Muhammad Sameer Arshad, Areesha Jawed, Adeena Musheer, Anousheh Awais Paracha, Ahmed Kamal Siddiqi, Neha Saleem Paryani, Izza Shahid, Muhammad Mustafa Memon

{"title":"Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.","authors":"Aymen Ahmed, Muhammad Umer Sohail, Muhammad Saad, Zara Naveed, Muhammad Sameer Arshad, Areesha Jawed, Adeena Musheer, Anousheh Awais Paracha, Ahmed Kamal Siddiqi, Neha Saleem Paryani, Izza Shahid, Muhammad Mustafa Memon","doi":"10.1080/14796678.2025.2506350","DOIUrl":"https://doi.org/10.1080/14796678.2025.2506350","url":null,"abstract":"Background: ST-segment elevation myocardial infarction (STEMI) is responsible for high morbidity and mortality rates globally. Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs. This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI.Methods: Randomized controlled trials (RCTs) were pooled from PubMed and Cochrane databases. A random-effects model calculated risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs).Results: Five trials (n = 4,915) were included. ARNIs significantly reduced major adverse cardiovascular events (MACE) (RR: 0.66, 95% CI [0.50, 0.86]; p = 0.002) and hospitalizations for heart failure (HHF) (RR: 0.67, 95% CI [0.49, 0.92]; p = 0.01). ARNIs also improved left ventricular ejection fraction (LVEF) (WMD: 2.60, 95% CI[1.53, 3.68]; p < 0.00001) and lowered NT-proBNP levels (WMD: -268.89, 95% CI[-422.35, -115.42]; p = 0.0006). No significant differences were observed in recurrent myocardial infarction, cardiovascular death, or safety outcomes - except for hypotension, which was significantly more common with ARNI use.Conclusions: ARNI therapy reduces MACE, HHF, and NT-proBNP levels and improves LVEF in patients with STEMI without increasing safety risks, except for hypotension. Further RCTs are needed to confirm these findings.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.6,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a meta-analysis. 射频消融治疗肥厚性阻塞性心肌病的疗效和安全性：一项荟萃分析。

IF 1.6

Future cardiology Pub Date : 2025-05-22 DOI: 10.1080/14796678.2025.2509368

Hashim Talib Hashim, Muhammad Osama, Muhammad Haris Khan, Safeena Khan, Nohela Rehman, Mohammedbaqer Ghuraibawi, Muhammad Abdullah Ali, Wajeeh Ur Rehman, Hafsa Arshad Azam Raja, Zeeshan Khan, Malak Bilal Hassan, Zaid Saad Abed Madhi

{"title":"Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a meta-analysis.","authors":"Hashim Talib Hashim, Muhammad Osama, Muhammad Haris Khan, Safeena Khan, Nohela Rehman, Mohammedbaqer Ghuraibawi, Muhammad Abdullah Ali, Wajeeh Ur Rehman, Hafsa Arshad Azam Raja, Zeeshan Khan, Malak Bilal Hassan, Zaid Saad Abed Madhi","doi":"10.1080/14796678.2025.2509368","DOIUrl":"https://doi.org/10.1080/14796678.2025.2509368","url":null,"abstract":"Background: Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic heart disease leading to obstructive hypertrophy. Radiofrequency ablation (RFA) is a minimally invasive alternative to traditional treatments. This review evaluates RFA's effectiveness and safety for HOCM.Methods: A systematic review and meta-analysis were performed on studies from PubMed, Cochrane, and clinicaltrials.gov up to August 2024. Studies comparing RFA outcomes before and after the procedure were included. Data were analyzed through Revman software, using random-effects models. The funnel plots and Egger test were used for publication bias. Subgroup analysis and sensitivity analysis were also performed.Results: This meta-analysis included 16 cohort studies and 2 case series, encompassing 727 patients with ages ranging from 10.4 to 62 years. The studies were conducted in various countries, including China, the USA, Germany, the UK, India, and Brazil. The analysis revealed significant improvements following radiofrequency ablation (RFA): the LVOT gradient at rest was reduced by MD -58.2 (CI: -71.2 to -56.93, p < 0.00001), and the provoked gradient decreased by MD -81.05 (CI: -97.67 to -64.42, p < 0.00001).Conclusion: RFA effectively reduces both LVOT gradients at rest and provoked, improves NYHA functional class, and decreases septal size in HOCM patients.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary. 了解转甲状腺蛋白淀粉样心肌病（atr - cm）患者在服用他法非底斯作为常规医疗保健的一部分时能活多久：一个简单的语言总结。

IF 1.6

Future cardiology Pub Date : 2025-05-20 DOI: 10.1080/14796678.2025.2492958

Pablo Garcia-Pavia, Arnt V Kristen, Brian Drachman, Martin Carlsson, Leslie Amass, Mathew S Maurer

引用次数: 0

The clinical role of closed loop stimulation pacemakers in the treatment of patients with sinus node dysfunction: a review. 闭环刺激起搏器治疗窦结功能障碍的临床作用综述。

IF 1.6

Future cardiology Pub Date : 2025-05-19 DOI: 10.1080/14796678.2025.2507464

Alessio Gargaro, Gianluca Biancalana, Giovanni Luca Botto, Michele Brignole

{"title":"The clinical role of closed loop stimulation pacemakers in the treatment of patients with sinus node dysfunction: a review.","authors":"Alessio Gargaro, Gianluca Biancalana, Giovanni Luca Botto, Michele Brignole","doi":"10.1080/14796678.2025.2507464","DOIUrl":"https://doi.org/10.1080/14796678.2025.2507464","url":null,"abstract":"Sinus bradycardia, sinoatrial block, sinus arrest, and bradycardia-tachycardia syndrome are manifestations of intermittent or persistent sinus node dysfunctions (SNDs). SND is classified as intrinsic, when related to an anatomic disease of sinoatrial cells, or extrinsic, when bradycardia is caused by inappropriate vagal outflow. Chronotropic incompetence is often associated with SND, especially in elderly patients. When symptoms are related to SND, pacemaker implantation is the recommended therapy, and rate-adaptive pacing modes are often preferred in cases of chronotropic incompetence. Closed-Loop Stimulation (CLS) is a rate-adaptive system based on continuous evaluation of contractility and contraction speed through the analysis of right-ventricular unipolar impedance trends during the systole of each cardiac cycle. An increase in contractility or contraction speed modifies the impedance trends, to which the CLS algorithm responds by adapting the pacing rate, and thereby heart rate and cardiac output. Therefore, CLS is integrated into the autonomic mechanisms of cardiac output regulation. This feature has drawn interest in the use of CLS in several forms of SND, from the treatment of intrinsic bradycardias to the prevention of vasovagal syncope and device-detected atrial fibrillation. We will examine the working principle of CLS and review the results of recent clinical investigations.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility and challenges of single-session percutaneous double valve in valve implantation in the elderly. 老年人单次经皮双瓣膜置入术的可行性与挑战。

IF 1.6

Future cardiology Pub Date : 2025-05-19 DOI: 10.1080/14796678.2025.2508108

Seifollah Abdi, Iraj Nazeri, Mohammad Hossein Mandegar, Babak Geraiely, Hamidreza Soleimani, Mehrdad Mahalleh, Sadaf Agahi, Amir Abdi, Farnoosh Larti

引用次数: 0

Identifying ventricular arrhythmia and sudden cardiac arrest in clinical notes of an electronic health record database. 在电子健康记录数据库的临床记录中识别室性心律失常和心脏骤停。

IF 1.6

Future cardiology Pub Date : 2025-05-18 DOI: 10.1080/14796678.2025.2506956

Neil Dhopeshwarkar, Charles Dharmani, Oluwatosin Fofah, Nora Tu, Nasser Khan, Tzuyung Douglas Kou, K Arnold Chan

{"title":"Identifying ventricular arrhythmia and sudden cardiac arrest in clinical notes of an electronic health record database.","authors":"Neil Dhopeshwarkar, Charles Dharmani, Oluwatosin Fofah, Nora Tu, Nasser Khan, Tzuyung Douglas Kou, K Arnold Chan","doi":"10.1080/14796678.2025.2506956","DOIUrl":"https://doi.org/10.1080/14796678.2025.2506956","url":null,"abstract":"Aim: Validating an operational algorithm for identifying ventricular arrhythmia and sudden cardiac arrest (VA/SCA) in electronic health record (EHR) data may be useful to minimize measurement bias in studies characterizing real-world VA/SCA risk; however, validation studies require an appropriate reference standard. We aimed to assess if adequate information is documented in unstructured clinical notes of a large EHR database to serve as a reference standard for future validation studies of VA/SCA.Methods: Twenty potential VA/SCA events were randomly selected from unstructured clinical notes of a large EHR database, TriNetX Dataworks - USA. These notes were reviewed to assess if key clinical elements were documented to confirm the occurrence of VA/SCA and describe their clinical features. These included explicit documentation of an acute event, electrocardiogram (ECG) findings, urgent medical interventions, and other elements.Results: Explicit documentation of an acute event was recorded for 17 patients (85.0%) and ECG findings were documented for 15 patients (75.0%). Generally, unstructured clinical notes also contained information about signs and symptoms, care setting, medical interventions administered, and event resolution.Conclusions: The unstructured clinical notes of a large EHR database contained the information necessary to serve as a reference standard for validation studies of a VA/SCA operational algorithm in EHR data.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-6"},"PeriodicalIF":1.6,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Direct oral anticoagulants in stroke prevention of atrial fibrillation patients: can we rely on them in all clinical scenarios? 直接口服抗凝剂预防房颤患者脑卒中：我们可以在所有临床情况下依赖它们吗？

IF 1.6

Future cardiology Pub Date : 2025-05-15 DOI: 10.1080/14796678.2025.2506915

Mattia Galli, Dominick J Angiolillo

引用次数: 0

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary. 转甲状腺素淀粉样变合并心肌病患者用乌曲西兰治疗：一个简单的语言总结。

IF 1.6

Future cardiology Pub Date : 2025-05-15 DOI: 10.1080/14796678.2025.2493019

Marianna Fontana, Julian D Gillmore, Ronald M Witteles, Ben Laryea, Marc Dworkin, Ann Payne, Fran Kochman, Satish Eraly, Mathew S Maurer

引用次数: 0